Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Nuclear factor-KB polypeptide inhibitor 4 and application thereof

A peptide inhibitor, -KB technology, applied in the direction of peptides, anti-inflammatory agents, peptide/protein components, etc., to achieve the effect of preventing or treating rheumatoid arthritis

Inactive Publication Date: 2014-05-07
NANTONG CHENGXIN AMINO ACID
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

2. Steroid hormones. Hormones are very good analgesic and anti-inflammatory drugs, but long-term use alone cannot improve the condition, but bring many side effects. Steroids can be used as a transitional second-line slow-acting drug before it takes effect, but the dosage should be limited. small, not too long
However, there are no well-developed nuclear factor-KB peptide inhibitors available for the treatment of RA

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] The immunoprotective effect of nuclear factor-KB polypeptide inhibitor 4 in collagen-induced mouse arthritis animal model

[0016] A collagen-type mouse arthritis animal model was constructed to study the therapeutic effect of nuclear factor-KB polypeptide inhibitor 4 on collagen-induced arthritis (CIA) in mice. Mice were used as experimental animals, 90 SPF grade DBA / 1 mice (provided by Sino-British SIPPR Lab. Animal Ltd, animal production license number: SCXK (Shanghai )2008-0016), male, 7-8 weeks old, body weight 18-22 g, were randomly divided into 6 groups, namely the normal control group, the model control group, 3 low, middle and high dosage groups of peptide inhibitor 4 (0.4, 0.8 , 1.6 mg / kg) and positive drug control group (methotrexate 2 mg / kg). In addition to the normal group, the mouse CIA model was established in each experimental group on day 0 by dissolving chicken cartilage type II collagen (cII) with 0.1 mol / l acetic acid into a 4 mg / ml solution and pla...

Embodiment 2

[0021] Protective effect of nuclear factor-KB polypeptide inhibitor 4 on the in vivo immune protection of adjuvanted rat arthritis animal model

[0022] An animal model of adjuvant arthritis in rats was constructed to study the therapeutic effect of nuclear factor-KB polypeptide inhibitor 4 on adjuvant arthritis (AA) rats. Rats were used as experimental animals, 90 SPF grade SD rats (provided by Sino-British SIPPR Lab. Animal Ltd, animal production license number: SCXK (Shanghai) 2008 -0016), male, weighing 140 g-160 g, were randomly divided into 6 groups, namely the normal control group, the model control group, and 3 dose groups of nuclear factor-KB peptide inhibitor 4 low, middle and high doses (0.2, 0.4, 0.8 mg / kg) and positive drug control group (methotrexate 1 mg / kg). In addition to the normal group, on the 0th day, each experimental group established a rat AA model by injecting complete Freund's adjuvant containing inactivated Mycobacterium tuberculosis (H37RA, 10 mg / ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a nuclear factor-KB polypeptide inhibitor 4 and an application thereof, relates to the field of medicines, and in particular relates to a polypeptide capable of inhibiting a nuclear factor-KB and preventing and treating chronic infectious arthritis. The polypeptide has a brand new sequence of GILHGGVTRKDVVP. The polypeptide has the beneficial effect of being capable of treating the chronic infectious arthritis, thereby having a potential novel medicine development value.

Description

Technical field: [0001] The invention relates to the field of medicines, in particular to nuclear factor-KB polypeptide inhibitors for preventing and treating or preventing rheumatoid arthritis. Background technique: [0002] Rheumatoid arthritis (RA) is the most common clinical inflammatory joint disease and one of the main disabling factors. It is about 0.5%-1.0% in the world, and the incidence of RA is about 0.4% in my country. RA can occur at any age, and the incidence rate increases with age. The high-incidence age of women is 45-55 years old, and gender is closely related to the incidence of RA, with a male-to-female ratio of about 1:3. RA is a chronic systemic inflammatory disease of unknown etiology, with chronic, symmetrical, polysynovial arthritis and extra-articular lesions as the main clinical manifestations, and belongs to autoimmune inflammatory disease. Patients often have hand or wrist pain and swelling (especially the swelling on the back of the wrist)...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/08A61K38/10A61P19/02A61P29/00
Inventor 邢将军许刘华彭立军任世阔华俊国曹铭刘加根刘明明汪士金施新华刘伟峰严明
Owner NANTONG CHENGXIN AMINO ACID
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com